<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989400</url>
  </required_header>
  <id_info>
    <org_study_id>5181</org_study_id>
    <nct_id>NCT04989400</nct_id>
  </id_info>
  <brief_title>Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion</brief_title>
  <official_title>Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion in Women With Previous Caesarian Section: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to assess the effectiveness and safety of Ulipristal Acetate in the&#xD;
      management of 2nd trimester missed abortion along with misoprostol in pregnant women with&#xD;
      previous caesarean section versus the use of misoprostol only with placebo as regards the&#xD;
      time needed for abortion,Hypothesis: In pregnant women with 2nd trimester missed abortion&#xD;
      with previous caesarean section , Ulipristal Acetate may decrease the time interval to&#xD;
      achieve abortion when combined with Misoprostol in comparison to misoprostol alone.the&#xD;
      included women divided to 2 groups Group A: will receive Ulipristal acetate 30mg, starting&#xD;
      misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017.Group&#xD;
      B: will receive placebo then 12 hours later start misoprostol 100µg every 6 hours buccal&#xD;
      according to FIGO guidelines 2017. then we assess Induction-to-abortion interval time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction-to-abortion interval time.</measure>
    <time_frame>2 weeks</time_frame>
    <description>calculate the time needed from start of intervention till abortion occured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete evacuation between both groups</measure>
    <time_frame>2 weeks</time_frame>
    <description>number of patients experienced complete abortion between both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for hysterotomy</measure>
    <time_frame>2 weeks</time_frame>
    <description>number of patients underwent hysterotomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Induction of Second Trimester Abortion</condition>
  <arm_group>
    <arm_group_label>ulipristal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal Acetate</intervention_name>
    <description>Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.</description>
    <arm_group_label>ulipristal group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>ulipristal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: • Women with 2nd trimester missed abortions&#xD;
&#xD;
          -  Gestational age 13-26 weeks.&#xD;
&#xD;
          -  Women with a previous caesarian section scar,(para 1cs till para 4 cs).&#xD;
&#xD;
          -  Women counseled and chose medication abortion rather than surgical evacuation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with an accompanying medical disorder such as: Preeclampsia, Diabetes Mellitus&#xD;
             or Heart disease.&#xD;
&#xD;
          -  Primigravida women or non scarred uterus.&#xD;
&#xD;
          -  Women with previous myomectomy or hysterotomy scar or upper segment caesarean section&#xD;
             scar.&#xD;
&#xD;
          -  Induction of abortion in women with congenital fetal malformations or positive fetal&#xD;
             pulsations due to medical disorder.&#xD;
&#xD;
          -  Women with placenta previa .&#xD;
&#xD;
          -  Allergy or contraindications to either Ulipristal acetate or Misoprostol.&#xD;
&#xD;
          -  Women with inevitable abortion in the form of vaginal bleeding or uterine contractions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain SHams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbaseya</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sarah Safwat</investigator_full_name>
    <investigator_title>lecturer of obstetrics and gynaecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04989400/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04989400/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

